Table 2 Comparison between the proposed two-stage minimax and optimal designs with survival endpoint and Belin’s two-stage optimal design with survival endpoint, when the follow-up time is restricted to the clinically meaningful follow-up time tc=1 year
From: Two-stage optimal designs with survival endpoint when the follow-up time is restricted
Minimax design | Optimal design | Belin | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Power | θ | n 1 | n | c 1 | c | E S S 0 | n 1 | n | c 1 | c | E S S 0 | n | E S S 0 |
90% | 15 | 28 | 52 | -0.10 | -1.64 | 39.1 | 26 | 56 | -0.30 | -1.64 | 37.5 | 53 | 42.3 |
95% | 15 | 36 | 65 | -0.09 | -1.64 | 49.5 | 33 | 70 | -0.29 | -1.64 | 47.3 | 65 | 52.6 |
90% | 30 | 30 | 52 | 0.30 | -1.64 | 43.6 | 30 | 55 | -0.04 | -1.64 | 42.2 | 53 | 44.6 |
95% | 30 | 40 | 65 | 0.19 | -1.64 | 54.3 | 40 | 69 | -0.20 | -1.64 | 52.2 | 65 | 54.8 |
90% | 50 | 34 | 52 | 0.51 | -1.64 | 46.5 | 32 | 54 | 0.32 | -1.63 | 45.7 | 52 | 47.0 |
95% | 50 | 44 | 65 | 0.46 | -1.64 | 58.2 | 42 | 68 | 0.17 | -1.64 | 56.7 | 64 | 57.5 |